389
Views
11
CrossRef citations to date
0
Altmetric
Research Articles

Prevalence of early discontinuation and associated factors among a retrospective cohort of etonogestrel contraceptive implant users

, , &
Pages 475-479 | Received 14 Dec 2018, Accepted 07 Sep 2019, Published online: 23 Sep 2019

References:

  • Bahamondes L, Brache V, Meirik O, et al. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls. Hum Reprod. 2015;30:2527–2538.
  • Ezegwui HU, Ikeako LC, Ishiekwene CI, et al. The discontinuation rate and reasons for discontinuation of Implanon at the family planning clinic of University of Nigeria Teaching Hospital (UNTH) Enugu, Nigeria. Niger J Med. 201120:448–450.
  • Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care. 2008;13:4–12.
  • Harvey C, Seib C, Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland. Aust Contracept. 2009;80:527–532.
  • Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception. 2006;74:287–289.
  • Law A, Liao L, Lin J, et al. Twelve-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in women aged 18–44: a retrospective claims database analysis. Contraception. 2018;98:120.
  • Short M, Dallay D, Omokanye S, et al. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: one-year results of an observational study. Eur J Contracept Reprod Health Care. 2012;17:79–88.
  • Teunissen AM, Grimm B, Roumen FJ. Continuation rates of the subdermal contraceptive Implanon® and associated influencing factors. Eur J Contracept Reprod Health Care. 2014;19:15–21.
  • Casey PM, Long ME, Marnach ML, et al. Bleeding related to etonogestrel subdermal implant in a US population. Contraception. 2011;83:426–430.
  • Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 2009;91:1646–1653.
  • Mansour D, Korver T, Marintcheva-Petrova M, et al. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13: 13–28.
  • Casey PM, Long ME, Marnach ML, et al. Association of body mass index with removal of etonogestrel subdermal implant. Contraception. 2013;87:370–374.
  • Ireland LD, Goyal V, Raker CA, et al. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding. Contraception. 2014;90:253–258.
  • Allsworth JE, Secura GM, Ajibade OO, et al. Differences in contraceptive discontinuation among Black and White women: evidence from the contraceptive CHOICE project. J Womens Health. 2018;27:599–606.
  • Sznajder KK, Tomaszewski KS, Burke AE, et al. Incidence of discontinuation of long-acting reversible contraception among adolescent and young adult women served by an urban primary care clinic. J Pediatr Adolesc Gynecol. 2017;30:53–57.
  • Modesto W, Bahamondes MV, Bahamondes L. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives. Hum Reprod. 2014;29:1393–1399.
  • Rubenstein J, Rubenstein P, Barter J, et al. Counselling styles and their effect on subdermal contraceptive implant continuation rates. Eur J Contracept Reprod Health Care. 2011;16:225–228.
  • Westhoff C, Jones K, Robilotto C, et al. Smoking and oral contraceptive continuation. Contraception. 2009;79:375–378.
  • Friedlander E, Kaneshiro B. Therapeutic options for unscheduled bleeding associated with long-acting reversible contraception. Obstet Gynecol Clin North Am. 2015;42:593–603.
  • Guiahi M, McBride M, Sheeder J, et al. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial. Obstet Gynecol. 2015;126:508–513.
  • Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. Eur J Contracept Reprod Health Care. 2016;21:361–366.
  • Hoggart L, Newton VL, Dickson J. “I think it depends on the body, with mine it didn’t work”: explaining young women’s contraceptive implant removal. Contraception. 2013;88:636–640.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.